Results 141 to 150 of about 84,780,597 (237)

Harnessing ferroptosis from multilayer defense networks to nanoplatforms for specific cancer therapy

BMEMat, EarlyView.
Nanomaterials target metabolically‐regulated ferroptosis for cancer therapy. Iron‐based or alternative nanoplatforms integrate ferroptosis with chemotherapy, immunotherapy, or radiotherapy. They enable stimulus‐responsive therapies (photothermal, photodynamic, sonodynamic) activated by near‐infrared, light, or ultrasound, achieving potent synergistic ...
Xinyue Xu, Xuejian Wang, Wenyan Jiang, Wan Hairul Anuar Kamaruddin, Chunyan Fang, Pengfei Zhang   +5 more
wiley   +1 more source

Do 5-alpha reductase inhibitors decrease the risk of recurrent gross hematuria in patients who have had a transurethral prostatectomy? [PDF]

Can Urol Assoc J, 2021
Welk B, Reid J, Ordon M, Campbell J, Dixon S.   +4 more
europepmc   +1 more source

Nanomedicine‐driven innovations in postoperative cancer immunotherapy: Remodeling tumor microenvironment and precision delivery strategies

BMEMat, EarlyView.
Nanomedicine‐Driven Strategies for Suppressing Postoperative Tumor Recurrence. This schematic illustrates three pivotal nanomedical strategies that synergistically counteract recurrence by targeting residual disease and the immunosuppressive tumor microenvironment within the surgical cavity.
Lisong Pang, Zhuomin Wang, Zhenhua Jin, Ahmed H. Ghonaim, Hengcheng Zhang, Xinyu You, Jinzhuo Ning, Jiaqing Cao, Yang Liu   +8 more
wiley   +1 more source

Modulating testosterone pathway: a new strategy to tackle male skin aging?

Clinical Interventions in Aging, 2012
Philippe Bernard1, Thomas Scior2, Quoc Tuan Do11Greenpharma SAS, Orléans, France; 2Pharmacy Department, Benemerita Universidad Autonoma de Puebla, Puebla, MexicoAbstract: In men, the level of testosterone decreases with age. At the skin level, the
Bernard P, Scior T, Do QT
doaj  

Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality

BMEMat, EarlyView.
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim, Marwa Ahmed El‐Naka, Wedad M. Nageeb, Atta Ullah Khan, Noura M. Seleem, Aliaa Abdelghafar, Doaa Zamel, Yang Liu, Qigai He, Wentao Li   +9 more
wiley   +1 more source

Frontal fibrosing alopecia: efficacy of treatment modalities

International Journal of Women's Health, 2019
A Caresse Gamret,1 V Sumanth Potluri,1 Karthik Krishnamurthy,2 Raymond M Fertig31Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA; 2Division of Dermatology, Orange Park Medical Center, Orange ...
Gamret AC, Potluri VS, Krishnamurthy K, Fertig RM   +3 more
doaj  

Defect‐engineered tungsten oxide nanowires as redox‐metabolic nanozymes for gut inflammation‐infection syndromes

BMEMat, EarlyView.
Defect‐engineered WO3 nanowires serve as a multifunctional nanozyme platform to treat IBD complicated by Salmonella co‐infection. By integrating catalytic ROS/RNS scavenging and targeted metabolic interference of pathogens via molybdenum substitution, these nanowires effectively resolve intestinal oxidative stress, inhibit infection, and restore ...
Yifan Yuan, Shipeng Zhang, Mingxuan Liu, Xurui Hou, Yizhi Dai, Weiyu Zhang, Zhongwei Yang, Xiaoyu Zhang, Jiahui Mao, Mingge Wang, Xin Yang, Ping Zhang, Hui Wang, Jing Liu   +13 more
wiley   +1 more source

Patients with Chronic Inflammatory Diseases Can Experience Higher Exposure of Small Molecule Drugs than Healthy Volunteers: An Analysis of Recently Approved Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Chronic inflammation has long been known to downregulate the activity of certain cytochrome P450 (CYP) enzymes—the main enzymes responsible for the phase I metabolism of many small molecule drugs—potentially leading to higher exposures in patients with chronic inflammatory diseases compared to healthy volunteers. Neglecting this potential difference in
Johannes Tillil, Sathej Gopalakrishnan, Jennifer Dong, Karthik Venkatakrishnan, Charlotte Kloft, Wilhelm Huisinga, Lena Klopp‐Schulze   +6 more
wiley   +1 more source

5α-Reductase Inhibitors and Risk of Kidney and Bladder Cancers in Men with Benign Prostatic Hyperplasia: A Population-Based Cohort Study. [PDF]

Cancer Epidemiol Biomarkers Prev, 2023
Doherty N, Cardwell CR, Murchie P, Hill C, Azoulay L, Hicks B.   +5 more
europepmc   +1 more source

Comprehensive Evaluation of Commercial Antibodies for High Sensitivity Detection of EPO‐Doping on Western Blots

Drug Testing and Analysis, EarlyView.
A large‐scale evaluation of 164 commercially available anti‐human EPO antibodies was conducted to identify an alternative to clone AE7A5 anti‐EPO antibody used in doping control for the detection of erythropoiesis‐stimulating agents (ERAs) on Western blots.
Christian Reichel, Günter Gmeiner, Hans Geyer, Mario Thevis   +3 more
wiley   +1 more source